<DOC>
	<DOCNO>NCT00602797</DOCNO>
	<brief_summary>This phase II trial study side effect well vinorelbine tartrate paclitaxel work treat old patient advance non-small cell lung cancer . Drugs use chemotherapy , vinorelbine tartrate paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Vinorelbine Tartrate Paclitaxel Treating Older Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To assess safety efficacy combination vinorelbine paclitaxel administer weekly elderly patient advance non-small cell lung cancer . II . To assess response rate combination vinorelbine paclitaxel administer weekly elderly patient advance non-small cell lung cancer . III . To assess quality life elderly patient advance non-small cell lung cancer administration weekly paclitaxel vinorelbine . OUTLINE : Patients receive vinorelbine tartrate intravenously ( IV ) 6-10 minute paclitaxel IV 1 hour weekly 6 week . Treatment repeat every 8 week 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Pathologically proven nonsmall cell lung cancer evidence distant metastases/malignant pleural effusion Measurable disease image study 2 dimension No previous therapy either paclitaxel vinorelbine , chemotherapy past five year Patients previous resection lung cancer present recurrent disease eligible Patients prior malignancy include , provide diseasefree least five year Patients adequately treat basal cell squamous cell carcinoma skin , adequately treat carcinoma insitu cervix hormone sensitive prostate cancer eligible Karnofsky score &gt; = 70 ( Eastern Cooperative Oncology Group [ ECOG ] 02 ) White blood cell ( WBC ) count &gt; = 3,500/mm^3 , OR Absolute neutrophil count ( ANC ) &gt; = 1,500/ul Platelet count &gt; = 100,000/mm^3 Serum creatinine less 1.5 time upper limit normal Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 1.5 time upper limit normal Serum alkaline phosphatase less 2.5 time upper limit normal No active serious infection condition preclude chemotherapy Nonpregnant nonnursing Men woman reproductive potential may participate unless agree use effective contraceptive method study Able give inform consent Able return treatment followup specify protocol Known hypersensitivity component vinorelbine paclitaxel require drug study Any comorbidity condition , opinion investigator , may interfere assessment procedure protocol Inability fulfill requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>